CCM
ADCT icon

CAAS Capital Management’s ADC Therapeutics ADCT Stock Holding History

CAAS Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,958
Closed -$262K – 637
2021
Q4 		$262K Buy
+12,958
New +$312K 0.01% 635
2020
Q4 		– Sell
-35,000
Closed -$1.16M – 818
2020
Q3 		$1.16M Hold
35,000
– – 0.03% 322
2020
Q2 		$1.64M Buy
+35,000
New +$1.33M 0.05% 228

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAAS Capital Management's ADCT Position: Q1 2022 in Review

CAAS Capital Management sold out of ADC Therapeutics (ADCT) in Q1 2022, closing a stake of 12,958 shares — an estimated $262K sold.

CAAS Capital Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $1.64M in Q2 2020. 49 funds tracked by Wall St. Rank hold ADCT as of Q1 2022.

  • CAAS Capital Management reported no remaining ADC Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 12,958 ADC Therapeutics shares in Q1 2022, an estimated $262K.
  • CAAS Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • CAAS Capital Management's ADC Therapeutics position peaked at $1.64M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.